# Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

> **NCT00035984** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 734 (actual)

## Conditions studied

- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

- **DRUG:** AC2993
- **DRUG:** AC2993
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00035984
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-08
- **Final completion:** 2003-08
- **Target enrollment:** 734 (ACTUAL)
- **Last updated:** 2015-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035984, "Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00035984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*